Phillip M. Glamuzina, PA-C

Phillip Glamuzina practices at Buffalo Surgery Center LLC in Buffalo, New York.

Phillip Glamuzina's NPI, 1013251040, was assigned on November 15, 2012. Phillip Glamuzina holds New York license 0299913.

Phillip Glamuzina's primary practice is Buffalo Surgery Center LLC, at 3925 Sheridan Dr, Buffalo, NY 14226 in Erie County. The practice phone is (716) 250-6520.

Phillip Glamuzina's primary practice is Buffalo Surgery Center LLC in Buffalo, New York. The medical group on file is Excelsior Orthopaedics. Dmand AI also links Phillip Glamuzina to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Phillip Glamuzina practices. Vendor and product names are available with a free account.

Physician assistant is Phillip Glamuzina's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Phillip Glamuzina is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Dmand AI has Phillip Glamuzina's licenses on file in 2 states: New York and Pennsylvania.

Dmand AI lists fibromyalgia and chronic pain, lower back pain, neck pain and spine problems and thoracic spine disorders among the conditions Phillip Glamuzina treats.

CMS data shows 407 Medicare services from Phillip Glamuzina across 14 procedure codes in 2024, for 165 Medicare patients. Medicare paid $13,924 for them. Every service was in an office.

CMS counts 165 Medicare patients who saw Phillip Glamuzina in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have high cholesterol, and 70% have arthritis. 19% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Phillip Glamuzina's median patient age at 56, with 64% women.

In 2024, Phillip Glamuzina wrote 140 Medicare Part D claims for 128 patients. 99% of them were for generic drugs. CMS names the drug for 105 of them, across 2 drugs with 11 or more claims each, at $690 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Phillip Glamuzina for performance year 2024, reported as part of a group. Phillip Glamuzina accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Phillip Glamuzina from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Vertex Pharmaceuticals Incorporated paid the most, $125.